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ABSTRACT
Amphetamine abuse is increasing worldwide. To
understand the mechanisms underlying addiction, as well as
the psychosis that may develop with amphetamine use, animal
models of behavioral sensitization are often employed. In
the present study, markers of neuronal and glial toxicity
(i.e., GFAP, DAT, GLT-1) were used'to assess cellular
changes following amphetamine-induced behavioral
sensitization. As expected, repeated amphetamine treatment
induced behavioral sensitization and conditioned activity
in adult rats. Amphetamine pretreatment resulted in
increased GFAP levels within the basal ganglia
thalamocortical "motor" pathway. Additionally, enhanced
DAT levels were evident in the basal ganglia
thalamocortical "limbic" pathway, while GLT-1 levels were
unchanged. The presence of gliosis (i.e., increased GFAP
levels) supports the possibility that behavioral
sensitization may be due, in part, to neurotoxicity.
However, the lack of change in GLT-1 (a marker of glial
cell toxicity) and an increase, rather than a decrease, in
DAT levels (an indirect measure of DA neurotoxicity) is not
consistent with a toxicity hypothesis of behavioral
iii
sensitization. Instead, the latter results suggest the
presence of neuroprotective and/or homeostatic mechanisms
that may mediate both the development of behavioral
sensitization and addiction.
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CHAPTER ONE
THE CLINICAL RELEVANCE OF
AMPHETAMINE STUDIES
Prevalence of Abuse
Amphetamine abuse is on the rise. In a 9-year period
from 1985 to 1994, the number of countries reporting abuse
of amphetamine-type substances (ATS; e.g., d-amphetamine,
methamphetamine, ephedrine, pseudoephedrine, etc.) tripled
(United Nations Drug Control Programme [UNDCP], 1996). In
addition, 35 countries providing ATS statistics revealed a
49% net increase in the abuse of ATS. This increase was
higher than that documented for either cocaine or heroin
(39% and 30% respectively; UNDCP, 1996) . Not exempt from
the ATS problem, the United States experienced a
particularly sharp rise in the number of individuals
misusing ATS, with levels peaking at an estimated 2.4
million persons in 1993 (UNDCP, 1996). It is clear that
the ATS epidemic continues to spread, as data provided by
the United States (1993-1999) show ATS treatment admissions
increasing 131% nationwide, with 14 states claiming
increases of 250% or more (SAMHSA, 2001).
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Historical Background
Evolution of Clinical Usage and Utility
The role of ATS in clinical practice has changed
significantly over the past 60 years. Originally
synthesized in 1887, amphetamine was first made available
to the public as a nasal inhaler in 1932, followed five
years later by tablet form (Grinspoon & Bakalar, 1979;
Keltner & Folks, 1997; LeBlanc, Kalant, & Kalant, 1973;
Perrone, 1998; UNDCP, 1996). For many years after its
introduction, amphetamine was considered a cure-all for
everything from head injuries and irritable colon to
anhedonia and difficulty in concentrating (Bett, 1946;
Seymour & Smith, 1987; UNDCP, 1996). It was even listed as
a facilitator for psychotherapy in a 1954 psychiatric text
(Connell, 1958). Since the Controlled Substances Act
convention in 1971, the limited therapeutic use of ATS has
been recognized (Benet, 1996; UNDCP, 1996). Presently, ATS
are prescribed mainly for the treatment of attention
deficit/hyperactivity disorder, obesity, and narcolepsy
(DEA, 2000; Hoffman & Lefkowitz, 1996; Keltner & Folks,
1997; Logan, 2001; Perrone, 1998; UNDCP, 1996).
Initially, lack of appreciation for ATS addiction
potential, coupled with overconfidence in the therapeutic
2
efficacy of ATS drugs, precipitated lax prescription
policies and abuse. It was not until the 1950s that
governmental controls existed for ATS (Babayan, Astahova,
Lepakin, & Lopatin, 1984; Connell, 1958; Konuma, 1994).
Even then, the risk connected with ATS use was thought to
be minimal. This was evident by its Schedule IV placement
(indicating minimal risk and high therapeutic value) and
its continued wide availability as an over-the-counter drug
(Connell, 1958).
Unfortunately, the favorable view of ATS belied their
dangers. Problems stemming from ATS usage were observed
shortly after their appearance on the market. In fact, in
1938, Young'and Scoville reported three incidences of
psychosis related to amphetamine use (Young & Scoville,
1938). Sporadic reports of psychosis by other clinicians
followed (Connell, 1958). However, physicians were
hesitant to attribute psychosis directly to ATS use, and
instead felt that these psychoses were rare occurrences in
individuals already predisposed to psychiatric illness
(Bett, 1946; Connell, 1958). Further, the apparent lack of
classic withdrawal symptoms caused many clinicians to argue
that addiction to an ATS was not possible (Bett, 1946;
LeBlanc et al., 1973), even though information detailing
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widespread ATS abuse in Japan was available following that
country's inundation with the drug after WWII (Kalant,
1973; Konuma, 1994; Tatetsu, 1972; UNDCP, 1996).
Reluctance to acknowledge the possible hazards of ATS use,
coupled with their presumed therapeutic benefits,
precipitated generous and lax prescribing of these drugs
and their general overuse (Kalant, 1973; UNDCP, 1996).
Amphetamine-Type Substance Addiction Controversy
By the 1960s, ATS abuse had spread throughout various
European countries as well as North America (Kalant, 1973;
Pickering & Stimson, 1994). Although ATS abuse was quickly
becoming a global problem, experts disagreed as to whether
ATS were addictive. The main point of contention was
whether or not withdrawal symptoms accompanied ATS
abstinence (Kalant, 1973). Many experts were using the
characteristics of opiate withdrawal to define the
symptomology of physical dependence. Using this frame of
reference, these professionals determined that
psychological depression, prolonged sleep, and increased
appetite following the cessation of ATS use was simply a
result of. the fatigue that follows heightened physical
alertness and exertion (LeBlanc et al., 1973). Those
professionals who disagreed felt that these behavioral
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manifestations constituted withdrawal symptoms, thus
indicating that ATS produced a physical dependence and were
potentially addictive (LeBlanc et al., 1973). The latter
position was subsequently supported by sleep studies
showing that changes in REM cycling were dependent upon
previous ATS history and level of current exposure
(Caldwell & Caldwell, 1997; Lin et al., 2000; Nicholson &
Stone, 1981; Oswald & Thacore, 1963; Radulovacki & Zak,
1981; Watson, Hartmann, & Schildkraut, 1972).
In response to the continuing disagreement over the
definition of addiction, the World Health Organization
(WHO) revised its conceptualization of addiction to reflect
a continuum of addictive symptomology. WHO changed their
terminology to reflect this paradigm shift, implementing
the term "drug dependence" followed by a qualifier (the
drug of abuse) and specifying the dependence
characteristics for that particular substance (Kalant,
1973) .
High-Risk and Limited Therapeutic Application
Determine Amphetamine-Type Substance Placement
Under the Controlled Substances Act
Following the 1971 Convention on Psychotropic Drugs,
ATS were reclassified as Schedule II substances as defined
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by the Controlled Substances Act. Under this act, drugs
are classified under one of four schedules based upon
therapeutic utility and level of health risk with lower
schedule numbers denoting less utility and higher risk
(Benet, 1996; UNDCP, 1996). As Schedule II drugs, ATS are
considered drugs'of■limited clinical use that carry a high
risk of dependence, both physical and psychological, and
abuse (Benet, 1996; DEA, 2000). This change in Schedule
placement, from level IV to level II, brought about
stricter controls of ATS and a decrease in indiscriminate
prescribing practices (Benet, 1996) . However, a curious
discrepancy still remains as ATS continue to be readily
available in many over-the-counter preparations (Keltner &
Folks, 1997; Perrone, 1998; Soutullo, Cottingham, & Keck,
1999; UNDCP, 1996). The stricter control of ATS has also
resulted in a decline in regulated manufacturers as well as
a substantial reduction in the amount of ATS being diverted
from licit to illicit markets (DEA, 2000; UNDCP, 1996).
Even so, the paradoxical Schedule IV placement of ATS
precursors, the relative simplicity of ATS synthesis, and
the ability of small clandestine laboratories to produce
ATS virtually anywhere, has allowed the illicit manufacture
6
of ATS to flourish (Logan, 2001; Mayrhauser, Brecht, &
Anglin, 2002; Rawson, Anglin, & Ling, 2002; UNDCP, 1996).
Societal Impact of Amphetamine-Type 
Substance Abuse
Amphetamine-Type Substance Use for Both Medical
and Non-Medical Purposes Remains High
ATS are now routinely prescribed for only a limited
number of clinical indications, namely attention deficit/
hyperactivity disorder, obesity, and narcolepsy (Logan,
2001; Hartman, 1995; Hoffman & Lefkowitz, 1996; Mitler,
1994; Perrone, 1998). Even though there are only three
medically approved reasons for ATS use, the number of
persons receiving this pharmacotherapy is substantial. It
has been reported that 3% of children worldwide are
diagnosed with attention deficit/hyperactivity disorder, 
with 0.2%-100% (depending on geographic region) receiving
medication for this disorder (Safer & Krager, 1988; Simeon,
Wiggins, & Williams, 1995; UNDCP, 1996). Further, it is
estimated that 30%-50% of middle-aged adults in
industrialized nations suffer from obesity, and that the
prevalence rate of narcolepsy is 0.1% globally (UNDCP,
1996). With the long-term treatment of these conditions
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often necessary, the potential for an escalation in ATS
addiction and abuse seems great.
The use of ATS for non-medicinal purposes has also
increased. The rise in the occupational and recreational
use of ATS has been attributed to both their CNS effects as
well as commonly held misconceptions regarding their
presumed safety (DEA, 2000; Hando, Topp, & Hall, 1997;
Pickering & Stimson, 1994; Rawson et al., 2002). ATS are
sympathomimetics that induce subjective feelings of
increased energy, mental acuity, concentration, and
alertness, as well as an elevation in mood (Hoffman &
Lefkowitz, 1996; Keltner & Folks, 1997; UNDCP, 1996; Wesson
& Smith, 1979). These properties have made ATS attractive
for those seeking greater endurance and mental performance
(such as truck drivers, construction workers, athletes, and
students), in addition to those seeking an overall feeling 
of well-being, euphoria, and greater self-confidence
(Babcock & Byrne, 2000; Seymour & Smith, 1987; Pickering &
Stimson, 1994; Rawson et al., 2002; UNDCP, 1996).
Popularity of ATS are further enhanced by their public
image as a relatively harmless drug, their ease of
availability, as well as their longevity of effect and
cheaper cost relative to cocaine (Mayrhauser et al., 2002;
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Rawson et al., 2002; UNDCP, 1996). The proliferation of
ATS usage is reflected not only by increases in the illegal
manufacture and trafficking of these drugs, but also by
increases in the number of ATS-related emergency room' and
rehabilitation clinic admissions (Baberg, Nelesen, &
Dimsdale, 1996; DEA, 2000, 2002; SAMHSA, 2001; UNDCP,
1996).
Economic Costs
Chronic ATS use results in increased financial costs
both to individuals who use ATS and to society at large.
Individuals who engage in chronic ATS use can experience
medical complications of both a physical and psychological
nature. Possible physical consequences include: cerebral
hemorrhage, stroke, cardiac arrhythmias, seizures, and
liver damage (Babayan et al., 1984; Hoffman & Lefkowitz,
1996; Keltner & Folks, 1997; Logan, 2001; Seymour & Smith,
1987). Depending upon the method of ingestion, nasal
ulcers and hepatitis may also occur (Perrone, 1998; Seymour
& Smith, 1987; UNDCP, 1996). Psychological consequences of
ATS use include aggressive behavior, anxiety, and psychosis
(Asnis & Smith, 1979; Ellinwood, 1972; Hando, et al., 1997;
Hartman, 1995; Logan, 2001; UNDCP, 1996). For society, ATS
abuse results in greater economic costs due to loss of
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worker productivity, criminality, and increased health care
costs (Hando et al., 1997; Rawson et al., 2002; UNDCP,
1996).
Over the long term, economic costs resulting from ATS
use can be profound. Decreased business revenues due to
loss of worker productivity can result in increased
consumer costs for goods and services (UNDCP, 1996). This
decrement in worker productivity stems from memory and fine
motor skill impairment, general hyperactivity that is
unfocused and nonproductive, as well as an overall increase
in workplace accidents (UNDCP, 1996, p. 123; see also Cox &
Smart, 1970; Hando et al., 1997; Rawson et al., 2002; Simon
et al., 2002). Publicly supported governmental
expenditures are also required to provide for increased law
enforcement and judicial costs associated with ATS related
policing, litigation, and detention expenses. In fact,
since 1964 it has been recognized that there is a causal
relationship between ATS use and violent crime (Asnis &
Smith, 1979; Ellinwood, 1972; Kalant, 1973; Kramer, 1972).
Moreover, there is growing involvement of organized crime
syndicates as well as continuing increases in manufacture
and trafficking activities that necessitate greater law
enforcement resources (DEA, 2000; Rawson et al., 2002;
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UNDCP, 1996). ATS use also places a greater burden on
health care systems because of medical costs related to
physical, psychological, and rehabilitative treatment
(Rawson et al., 2002; UNDCP, 1996). The possibility of
greater elderly care costs exist as well, as it has been
suggested that aged individuals with a prior history of ATS
use may develop a unique dementia-type symptomology
(Schuster & Hartel, 1994).
Summary
The use of ATS for medical conditions that require
long-term treatment remains high. This is especially true
in cases of attention deficit/hyperactivity disorder. In
addition, occupational and recreational use of these drugs 
is on the rise. Considering the global extent of ATS
manufacture, trafficking, abuse, and related economic
costs, it is clear that further experimental research is
needed to more fully understand the long-term impact of ATS
on individuals and societies worldwide.
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CHAPTER TWO
BEHAVIORAL SENSITIZATION:
AN OVERVIEW
Behavioral Sensitization Defined
Behavioral sensitization is the enduring augmentation
of behavior following repeated intermittent exposure to
psychostimulants (e.g., cocaine or amphetamine) as well as
stressors (Antelman, Eichler, Black, & Kocan, 1980;
Badiani, Cabib, & Puglisi-Allegra, 1992; Diaz-Otanez,
Capriles, & Cancels, 1997; Kalivas & Stewart, 1991; Kozell
& Meshul, 2001; Piazza, Deminiere, le Moal, & Simon, 1990;
Post, Weiss, & Pert, 1988, 1992). This behavioral
augmentation is most often manifested as increased
locomotor activity and/or stereotypy and varies in degree
of expression depending upon both the prior level of
stimulant exposure and dose of the challenge drug (Segal &
Kuczenski, 1987; Wolf, Dahlin, Hu, Xue, & White, 1995).
Sensitization has been observed in various species
(Machiyama, 1992; Robinson & Becker, 1986), and is thought
to be a useful paradigm for the study of addiction,
psychosis, and neural plasticity (Aizenstein, Segal, &
Kuczenski, 1990; Post et al., 1988; Robinson & Becker,
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1986; Segal & Schuckit, 1983; Strakowski, Sax, Setter, &
Keck, 1996'; Wolf, 1998) .
Sensitization: A Model for Addiction, Psychosis 
and Neural Plasticity
Behavioral Sensitization and-Addiction ■
The intermittent consumption of psychomotor stimulants
by humans, often referred to-as "runs"/' resembles the
intermittent administration schedules that are known to
reliably induce behavioral sensitization in animals
(Kramer, 1972; Post & Weiss, 1988; Segal & Kuczenski,
1999). As with animals, humans experiencing
psychostimulant-induced sensitization often show both
stereotypy, in the form of jaw grinding, picking of the
skin, and pundning (a preoccupation with objects involving
repetitive analyzation, categorization, and polishing), as
well as post-stereotypy locomotion manifested as periods of
sustained hyperactivity (Brady, Lydiard, Malcolm, &
Ballenger, 1991; de Leon, Antelo, & Simpson, 1992;
Ellinwood, 1972; Elpern, 1988; Kramer, 1972; Satel,
Southwick, & Gawin, 1991b; Schi0rring, 1981). These
behaviors are analogous to the gnawing, grooming, and
increased locomotor activity exhibited by sensitized rats
(Machiyama, 1992; Schiorring, 1981; Segal & Schuckit, 1983)
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In addition to these behavioral changes, repeated
psychostimulant exposure modifies a variety of neuronal
mechanisms underlying reward and motivational processes
(Grace, 1995; Kalivas & Duffy, 1990; Robinson & Berridge,
1993; White & Wolf, 1991; Wolf et al., 1995). For example,
repeated cocaine exposure causes postsynaptic dopamine (DA)
receptors to become increasingly more sensitive (Henry &
White, 1991) . When this occurs, doses of the drug that
would not normally be rewarding become gratifying,
resulting in continued self-administration (White & Wolf,
1991). Moreover, sensitization-induced changes in neuronal
functioning often are manifested as drug craving, which
further precipitates ongoing drug-seeking and is an
important component in drug relapse (Bartlett, Hallin,
Chapman, & Angrist, 1997; Ciccocioppo, Sanna, & Weiss,
2001; De Vries, Schoffelmeer, Binnekade, Mulder, &
Vanderschuren, 1998; De Vries, Schoffelmeer, Binnekade, &
Vanderschuren, 1999; Robinson & Berridge, 1993; Weiss et
al., 2001).
Sensitization and Psychosis
The symptomology of psychostimulant-induced psychosis
closely mimics that of paranoid schizophrenia (Brady et
al., 1991; Connell, 1958; Janowsky & Risch, 1979; Mitchell
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& Vierkant, 1991; Snyder, 1973; Yui, Ikemoto, Ishiguro, &
Goto, 2000). Presentation includes hallucinations
involving one or more modalities, delusions of persecution
and/or ideas of reference, and logorrhea (continuous,
repetitive speech), accompanied by clear consciousness
(Brady et al., 1991; Connell, 1958; Ellinwood, 1967, 1972;
Mitchell & Vierkant, 1991; Satel et al., 1991b; Schiorring,
1981). Although there are instances of pseudo-psychosis,
in which psychostimulant use precipitates the "break" that
signals the onset of schizophrenia, most individuals
suffering from psychostitnulant-induced psychosis experience
spontaneous remission of psychotic symptomology upon
cessation of drug intake (Angrist, 1994; Kalant, 1973;
Satel, Seibyl, & Charney, 1991a; Satel et al., 1991b;
Seymour & Smith, 1987).
Animal models of behavioral sensitization have long
been thought to be a useful paradigm for stimulant-induced
psychosis (Robinson & Becker, 1986; Schi0rring, 1981). This
is because animals show robust behavioral sensitization
when exposed to a drug regimen similar to that which
reliably produces psychotic symptoms in humans (Griffith,
Fann, & Oates, 1972; Kramer, 1972; Robinson & Becker, 1986;
Segal & Kuczenski, 1987; Segal & Schuckit, 1983).
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Furthermore, just as sensitization can be induced in
animals by a single acute exposure, or multiple low-dose
exposures, to a psychostimulant (Browne & Segal, 1977;
Kuczenski & Segal, 1999, 2001; Kuczenski, Segal, & Todd,
1997; Robinson, 1984; Ushijima, Carino, & Horita, 1995;
Vanderschuren et al., 1999; Wiaderna & Tomas, 2000),
psychotic symptomology can occur in humans following a
single exposure or multiple low-dose exposures (Connell,
1958; Hando et al., 1997; Kalant, 1973; Gold & Bowers,1978) .
Additional parallels can be drawn between behavioral
sensitization in animals and psychostimulant-induced
psychosis in humans. Specifically, four major
characteristics of sensitization, namely: persistence,
decreased latency to expression, increase in response
magnitude, and hypersensitivity of DA receptors are also
discernable in psychostimulant-induced psychosis (Li et
al., 1999; Post & Weiss, 1988; Wolf, 1998). In
psychostimulant-induced psychosis, the persistent quality
of sensitization is apparent because individuals remain
highly susceptible to recurrent episodes of psychosis when
exposed to the same psychostimulant again, even after years
of abstinence (Sato, 1992; Sato, Chen, Akiyama, & Otsuki,
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1983; Sato, Numachi, & Hamamura, 1992). The sensitization
qualities of decreased latency and increased response
magnitude are also evident in psychostimulant-induced
psychosis, because each subsequent psychotic experience is
marked by acceleration in symptom onset and an increase in
symptom intensity (Bartlett et al., 1997; Brady et al.,
1991; Satel et al., 1991b). Moreover, DA receptor
hypersensitivity is characteristic of both behavioral
sensitization and psychostimulant-induced psychosis (Sato
et al., 1983; see also Yui, Goto, Ikemoto) & Ishiguro,
1997, 2000).
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CHAPTER THREE
BEHAVIORAL MANIFESTATIONS
Factors Important for Behavioral 
Sensitization
Behavioral sensitization, once induced, may be
detectable for weeks, months, or longer (Post & Contel,
1983; Post & Weiss, 1988; Strakowski et al., 1996).
However, the robustness of the sensitized response is
influenced by several factors. These include: type of drug
and dosage (Browman, Badiani, & Robinson, 1998; Kuczenski &
Segal, 2001; Vanderschuren et al., 1997; Voikar et al.,
1999; Wiaderna & Tomas, 2000), subject age and gender
(Kuhn, Walker, Kaplan, & Li, 2001; Laviola, Wood, Kuhn,
Francis, & Spear, 1995; Melnick & Dow-Edwards, 2001; Sircar
& Kim, 1999; Zavala, Nazarian, Crawford, & McDougall,
2000), administration and testing schedules (Kuczenski &
Segal, 1988; Partridge & Schenk, 1999; Robinson, 1984;
Schenk & Partridge, 2000; Segal & Kuczenski, 1987), as well
as contextual cues (Anagnostaras & Robinson, 1996;
Battisti, Uretsky, & Wallace, 2000; Crombag, Badiani,
Maren, & Robinson, 2000; Post et al., 1988; White & Wolf,
1991).
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Stimuli Known to Induce Behavioral 
Sensitization
Although opioids and related drugs will induce
behavioral sensitization (Vanderschuren, De Vries, Wardeh,
Hogenboom, & Schoffelmeer, 2001; Voikar et al., 1999),
sensitization is most often induced through exposure to
psychstimulant drugs (Kalivas & Stewart, 1991; Segal &
Schuckit, 1983; White & Wolf, 1991). Of these, cocaine,
amphetamine, and methamphetamine are the most commonly used
(Aizenstein et al., 1990; Kuczenski & Segal, 2001; Schenk &
Partridge, 2000; Shimosato & Ohkuma, 2000) .
Psychostimulants are thought to have enduring effects on
behavior because of their similarity to stressors in their
physiological consequence, and cross-sensitization between
these two stimuli is well documented (Antelman et al.,
1980; Diaz-Otanez et al., 1997; Piazza et al., 1990;
Suzuki, Ishigooka, Watanabe, & Miyaoka, 2002; for reviews
see Antelman & Chiodo, 1983; Robinson, 1988; Stam,
Bruijnzeel, & Wiegant, 2000). The reciprocity between
psychostimulants and stressors appears to lie not only in
their shared ability to activate the sympathetic nervous
system, but also in their ability to alter the sensitivity
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of monoamine systems (Cole et al., 1990; Stam et al.,
2000).
Dosage Levels
Behavioral sensitization can be induced using either
low or high doses of psychostimulants (Robinson & Becker,
1986). However, behavioral manifestations vary according
to dosage level (Post & Weiss, 1988). When low dosage
levels are used, subjects primarily exhibit a state of
general hyperactivity that can be quantitatively measured
by their locomotor activity (Kuczenski & Segal, 1999; Post
& Contel, 1983; White & Wolf, 1991). At moderate doses, a
multiphasic pattern is routinely observed. This pattern is
characterized by initial increases in locomotion that
transition into a period of pronounced stereotypic
behaviors and conclude with post-stereotypy locomotion
(Kuczenski & Segal, 1999). As drug dosage levels increase,
behaviors become increasingly restricted with stereotypic
behaviors predominating (Kuczenski & Segal, 1988; Segal &
Kuczenski, 1987; Segal, Kuczenski, & Florin, 1995). In
addition to affecting the strength of expression, drug
dosage and number of exposures impacts the type of
behavioral sensitization expressed (i.e., context-dependent
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versus context-independent) as well as resistance to
extinction (Battisti et al. , 2000; but see Anagnostaras,
Schallert, & Robinson, 2002).
Subject Age and Gender
Subject age and gender affect both the speed of onset
and intensity of the sensitized response. Adult subjects
demonstrate a more robust sensitized response that develops
more quickly than in younger animals (Laviola et al., 1995;
Zavala et al., 2000). Similarly, females are more readily
sensitized and exhibit a more pronounced behavioral
response to psychostimulant challenge than do males (Kuhn
et al., 2001; Melnick & Dow-Edwards, 2001; Robinson,
Becker, & Presty, 1982; Sircar & Kim, 1999). This gender
difference is likely due to hormones that modulate
pituitary activity (Becker, Molenda, & Hummer, 2001; Chiu,
Kalant, & Le, 1998; Perrotti et al., 2001; Post, Contel, &
Gold, 1982).
Drug Administration and 
Testing Schedules
Drug administration and testing intervals are
critically important to the sensitization phenomenon
(Robinson & Becker, 1986). Although behavioral
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sensitization has been demonstrated following a single
acute injection of a psychostimulant, stereotypy and 
perseverative effects are most often observed following 
repeated drug exposure (Battisti et al., 2000; Kashihara,
Sato, Kazahaya, & Otsuki, 1986; Post & Weiss, 1988;
Robinson et al., 1982). When using a repeated exposure
paradigm, the time between treatments is an important
factor in determining whether sensitization or tolerance
will develop, with intermittent administration resulting in
sensitization and continuous exposure inducing tolerance
(Blanchet et al., 1995; Kalivas & Duffy, 1993; Nelson &
Ellison, 1978; Stewart & Badiani, 1993; Strakowski et al.,
1996). Similarly, administration schedules may also
determine whether,, and to what extent, neurotoxicity will
develop, with shorter intervals between exposures generally
having more deleterious effects (Huang, Tsai, Su, & Sim,
1999; Nelson & Ellison, 1978; Segal & Schuckit, 1983).
Therefore, when using a repeated administration paradigm to
induce behavioral sensitization, an intermittent schedule
consisting of administration intervals spanning one or more
days is preferable (Emmett-Oglesby, 1995; Kashihara et al.,
1986; Post & Contel, 1983; Robinson & Becker, 1986;
Strakowski et al., 1996; Tadokoro & Kuribara, 1990).
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Likewise, an abstinence period between drug pretreatment
and drug challenge lasting one or more days will result in
a more robust sensitized response (Post & Weiss, 1988;
Robinson & Becker, 1986; Robinson & Berridge, 1993). The
importance of these time constraints indicates that the
neurophysiological changes underlying behavioral
sensitization require an extended period of time to fully
develop (Antelman & Chiodo, 1983; Kalivas, 1995; Kashihara
et al., 1986).
The Role of Environmental Context in Behavioral 
Sensitization
A number of studies have shown that sensitized
responding is more robust when drug administrations are
given in a novel environment (Crombag et al., 2000;
Fraioli, Crombag, Badiani, & Robinson, 1999; Robinson,
Browman, Crombag, & Badiani, 1998; Tirelli & Terry, 1998).
This suggests that Pavlovian associations formed between
the drug and environmental cues (e.g., visual cues related
to the drug taking environment and drug paraphernalia,
tactile cues related to administration, etc.) influence the
development and expression of behavioral sensitization.
Additionally, stimulus generalization (a phenomenon in
which a stimulus that is similar in characteristic to the
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cue also comes to elicit the response) may also play a role
in behavioral sensitization (Post & Weiss, 1988). The
influence of Pavlovian cues appears to be particularly
important for young animals, or when adults are sensitized
using a single drug exposure paradigm ('Battisti et al.,
2000; Post & Contel, 1983; Robinson et al., 1982; Zavala et
al., 2000) .
In paradigms involving multiple drug administrations
and/or greater dosage levels, the importance of Pavlovian
associations for the development of behavioral
sensitization is of dispute. Some researchers argue that
Pavlovian processes and stimulus generalization principles
govern behavioral sensitization and do not diminish in
importance with an increased number of drug administrations
or larger drug dosages (Anagnostaras & Robinson, 1996; Post
& Weiss, 1988; Post et al., 1988; Tirelli & Terry, 1998).
Conversely, other researchers suggest that the importance
of environmental cues for behavioral sensitization
diminishes or becomes inconsequential as the number of drug
exposures increase or higher doses of psychostimulants are
used (Battisti et al., 2000; Browman et al., 1998; Robinson
et al,, 1998; Segal & Schuckit, 1983; Vezina & Stewart,
1990) .
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CHAPTER FOUR
NEURAL.. SUBSTRATES OF BEHAVIORAL
SENSITIZATION
The Two Components of Behavioral Sensitization: 
Induction and Expression
Behavioral sensitization is the physical manifestation
of complex neural changes within the CNS. Behavioral
sensitization is comprised of two distinct phases:
induction and expression (Karler, Chaudhry, Calder, &
Turkanis, 1990; Leith & Kuczenski, 1982; Stewart & Druhan,
1993; Vezina & Stewart, 1990). Moreover, each of these two
phases involves a different primary neural substrate. The
ventral tegmental area (VTA) is predominantly involved in
the induction of behavioral sensitization; whereas, the
nucleus accumbens (NAc) is important for expression (Cador,
Bjijou, & Stinus, 1995; Cornish & Kalivas, 2001a, 2001b;
Karler, Bedingfield, Thai, & Calder, 1997; Li & Wolf, 1997;
Pierce & Kalivas, 1997).
The Neural Basis of Behavioral Sensitization: 
Induction
Induction is the first phase of the sensitization
process (Wolf, 1998). Induction involves a transient
change in neuronal activity within the VTA caused by the
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actions of monoamines and amino acids (Bjijou, De
Deurwaerdere, Spampinato, Stinus & Cador, 2002; Cador, 
Bjijou, Cailhol, & Stinus, 1999; Cornish & Kalivas, 2001b;
Kalivas, 1995a; Kalivas & Alesdatter, 1993; Vezina & Queen,
2000). Psychostimulants increase the extracellular
concentrations of DA in the VTA (Fawcett & Busch, 1998).
High levels of extracellular DA activate presynaptic Di-like
receptors on glutamate pathways that project to the VTA
(Cador et al., 1999; Pierce, Bell, Duffy, & Kalivas, 1996).
Under basal conditions, the activation of these Di-like
receptors inhibits the release of glutamate (Cador et al.,
1995; Kalivas & Duffy, 1995). However, when high levels of
DA are released following psychostimulant activation, Di-
like receptors paradoxically stimulate the release of
glutamate (Kalivas & Duffy, 1995), thus activating N-
methyl-D-aspartate (NMDA) receptors located on DA cell
bodies in the VTA (Gnegy, 2000; Kalivas & Duffy, 1995,
1998). Stimulation of these NMDA receptors increases
extracellular levels of glutamate and y-amino butyric acid
(GABA) in the VTA, which ultimately results in burst firing
by DA neurons of the mesolimbic pathway (Kalivas, 1995a;
Suaud-Chagny, Chergui, Chouvet, & Gonon, 1992; Timmerman &
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Westerink, 1995). More precisely, glutamate (an excitatory
amino acid) stimulates DA neurons resulting in: (a)
increased somatodendritic DA release in the VTA, and (b) a
temporary change in the responsiveness of VTA DA neurons to
glutamate (Grace & Bunney, 1984; Kretschmer, 1999; Mereu,
Costa, Armstrong, & Vicini, 1991; White, Hu, Zhang, & Wolf,
1995).
The NMDA receptor stimulation associated with
induction also increases extracellular GABA (an inhibitory
amino acid) in the VTA (Timmerman & Westerink, 1995).
Stimulation of GABAa receptors, located on GABAergic
interneurons, normally acts to depress the firing rate of
DA neurons in the VTA. Therefore, activation of the GABAa
receptors disinhibits DA neurons, resulting in enhanced
somatodendritic DA release in the VTA (Klitenick, DeWitte,
& Kalivas, 1992). The increased extracellular DA in the
VTA then stimulates presynaptic Di-like receptors located on
terminals of a separate set of descending GABAb neurons (see
Fig. 1)(Klitenick et al., 1992). Stimulation of these Dx-
like receptors reduces GABA activity, further potentiating
somatodendritic DA release in the VTA (Bonci & Williams,
1996; Kalivas, 1995a; Klitenick et al., 1992; Walaas &
Fonnum, 1980). To summarize, psychostimulants modulate
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NAc
.... Dotted lines denote GABA projections
---- Solid line denotes DA projection
Figure 1. Illustration of the mesolimbic DA pathway 
projecting from the VTA to the NAc. GABA is released in 
the NAc, which directly stimulates GABAa receptors located 
on GABA interneurons and indirectly stimulates GABAb 
receptors located on VTA DA neurons (see inset).
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glutamate and GABA levels by indirectly stimulating NMDA 
receptors. By altering glutamate and GABA levels, 
psychostimulants increase extracellular concentrations of
DA in the VTA.
The importance of these mechanisms for the induction
of behavioral sensitization is supported by. studies showing
that: (1) Repeated administration of amphetamine into the
VTA (where DA cell bodies are located) results in
behavioral sensitization (Cador et al., 1995, 1999;
Perugini & Vezina, 1994; Vezina & Stewart, 1990); (2)
Repeated administration of amphetamine into the NAc, (where
DA terminals are located) does not induce behavioral
sensitization (Cador et al., 1995; Kalivas & Weber, 1988;
Swanson, 1982; Vezina & Stewart, 1990); (3) Robustness of
the sensitized response is directly related to the amount
of initial VTA stimulation (Cador et al., 1995; see also
Stewart & Vezina, 1989); and (4) Blocking NMDA receptors
inhibits the induction, but not the expression, of
behavioral sensitization (Druhan & Wilent, 1999; Karler et
al., 1990; Li et al., 1999; Johnson, Eodice, Winterbottom,
& Mokler, 2000; Vezina & Queen, 2000; but see Battisti,
Shreffler, Uretsky, & Wallace, 2000). Taken together,
these findings suggest that the induction of behavioral
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sensitization results from a complex interplay between
modulatory amino acid neurons (both glutamate and GABA) and
DA projection neurons.
The Neural Basis of Behavioral Sensitization: 
Expression
The NAc mediates the expression of behavioral
sensitization (Cornish & Kalivas, 2001a; Delfs, Schreiber,
& Kelley, 1990; Essman, McGonigle, & Lucki, 1993; Franklin
& Druhan, 2000; Kalivas & Duffy, 1990). The expression
phase is characterized by an augmentation of locomotion 
and/or stereotypy after a drug abstinence period (Wolf,
1998). For expression of behavioral sensitization to
occur, the physiological processes that underlie
sensitization must, in effect, "transfer" from the VTA to
the NAc (Wolf, 1998, p. 681).
The shift from the VTA to the NAc is initiated by
increased somatodendritic DA release in the VTA (see
previous section) (Kalivas, 1995a; Kimelberg, Goderie,
Higman, Pang, & Waniewski, 1990; Pierce & Kalivas, 1997;
White & Wolf, 1991). Specifically, the transient change in 
Di-like receptors that occurs during induction becomes long
lasting, as the presynaptic Dj-like receptors located in the
VTA (see Fig. 2) change from a temporary state of
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Dashed lines denote Glutamate projections 
Dotted lines denote GABA projections 
Solid lines denote DA projections
Figure 2. Illustration of the mesocortical and mesolimbic 
DA pathways showing the location of presynaptic DA Dj-like 
receptors. During the induction of behavioral
sensitization, these receptors become "supersensitive" 
serving to enhance DA release in the NAc by inhibiting GABA 
in the VTA and reducing glutamatergic stimulation of the DA 
neurons that project back to the PFC.
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subsensitivity to an enduring state of supersensitivity
(Hu, Brooderson, & White, 1992; Kalivas, 1995a; Sesack,
Deutch, Roth, & Bunney, 1989; White & Wolf, 1991; Wolf,
White, & Hu, 1994). This Di-like receptor supersensitivity
modulates NAc functioning in two main ways, both of which
appear to be important for the expression of behavioral
sensitization.
First, Dj-like receptor supersensitivity directly
alters the functioning of mesolimbic DA neurons projecting
from the VTA to the NAc. Specifically, stimulation of
supersensitive Di-like receptors attenuates GABAergic
functioning in the VTA (Bonci & Williams, 1996; Klitenick
et al., 1992). These changes in amino acid
neurotransmission act to enhance the firing rate of DA 
neurons projecting from the VTA to the NAc (Grace & Bunney,
1998). Thus, through this direct mechanism repeated
psychostimulant treatment results in augmented DA release
in the NAc.
Second, Di-like receptor supersensitivity serves to
potentiate DA release in the NAc by modulating glutamate
via two indirect pathways involving the prefrontal cortex
(PFC). Both pathways involve the stimulation of
presynaptic Di-like receptors located on glutamatergic
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neurons projecting from the PFC to the VTA. These
glutamate neurons synapse with mesocortical DA neurons that
project from the VTA to the PFC (see Fig. 3) (Takahata &
Moghaddam, 2000). Thus', • stimulation of these Di-like
receptors causes a reduction in glutamatergic stimulation
and, consequently, induces sustained hypoactivity in DA
neurons (Grace & Bunney, 1998) . ■
The lack of tonic inhibition by the mesocortical DA
neurons affects two distinct glutamatergic pathways that
originate at the PFC (see Fig. 3). One pathway projects
directly from the PFC to the NAc (PFC -> NAc) , and provides
glutamatergic excitation to the NAc (Berendse, Galis-DE
Graaf, & Groenewegen, 1992; Christie, Summers, Stephenson, 
Cook, & Beart, 1987; Montaron, Deniau, Menetrey, Glowinski, 
& Thierry, 1996). The other glutamate pathway projects
from the PFC to the VTA via the pedunculopontine tegmental
nucleus (PPTg; PFC -> PPTg -> VTA) (Lokwan, Overton, Berry, &
Clark, 1999; Sesack et al., 1989). When stimulated,
glutamate neurons projecting to the PPTg activate a second
glutamate pathway going from the PPTg to the VTA (Lokwan,
et al., 1999). This excess glutamate activity results in
further stimulation of DA neurons, which are already
supersensitive to glutamate because of the induction
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PFC
----- Dashed lines denote Glutamate projections
..... Dotted lines denote GABA projections
— Solid lines denote DA projections
Figure 3. Glutamatergic pathways originating in the PFC 
mediate accumbal activity via a direct pathway between the 
PFC and the NAc and via an indirect pathway that provides 
stimulation of the VTA by way of the PPTg.
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process (Youngren, Daly, & Moghaddam, 1993). Therefore, 
changes in Di-like receptor sensitivity in the VTA, brought 
about by the induction phase of sensitization, causes 
changes in the NAc, the structure responsible for the 
expression of behavioral sensitization. These changes
include increased DA release and' Di-like receptor
supersensitivity, which both result from psychostimulant-
induced alterations of these direct and indirect pathways.
In conclusion, Di-like receptors modulate the release
of DA from the VTA and glutamate from the PFC (see Fig. 3)
(Higashi, Inanaga, Nishi, & Uchimura, 1989; Kalivas &
Duffy, 1995, 1998; Vanderschuren & Kalivas, 2000).
Stimulation of Di-like receptors causes a decrease in GABA
at the VTA, as well as an increase in glutamate at both the
VTA and the NAc (Bonci & Williams, 1996; Kalivas, 1995a;
Kalivas & Duffy, 1995, 1998; Pierce & Kalivas, 1997;
Takahata & Moghaddam, 2000; Youngren et al., 1993) . The
action of these amino acids increases DA release in the
NAc. This increase in excitatory, and decrease in
inhibitory, impulses produces a positive feedback loop to
the VTA resulting in burst firing of dopamine neurons
(Kalivas & Duffy, 1995; Takahata & Moghaddam, 2000). Burst
firing of DA neurons increases DA release and,
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consequently, glutamate release (Bockstaele & Pickel, 1995;
Bond & Williams, 1996; Kalivas & Duffy, 1998; Mereu et
al., 1991; Pierce & Kalivas, 1997). Therefore, it is the
summation of amino acid impulses combined with inhibitory
dopaminergic input that modulates NAc activity and, thus,
the behavioral manifestations of sensitization (Kalivas,
1995a; Kretchmer, 1999; Vanderschuren & Kalivas, 2000).
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CHAPTER FIVE
GLUTAMATE AND BEHAVIORAL
SENSITIZATION'
The Widespread Influence 
of Glutamate
Glutamate neurons are located extensively throughout
the basal ganglia and related structures. For example,
glutamate neurons project bi-directionally between the PFC
and the medial dorsal thalamus (MDThai) , as well as
descending from the PFC to the NAc, VTA, and PPTg (Berends
et al., 1992; Christie et al., 1987; Montaron et al., 1996
Pierce & Kalivas., 1997; Sesack et al., 1989; Takahata &
Moghaddam, 2000; Tzschentke & Schmidt, 2000). The PFC
projection to the NAc is a direct one. However, the PFC
projection to the VTA is indirect, as the PFC innervates
the PPTg which, in turn, sends a glutamatergic projection
to the VTA (see Fig. 4) (Lokwan et al., 1999; Sesack et
al., 1989; Tzschentke & Schmidt, 2000).
As described in Chapter Four, glutamate projections
are critical for the induction of behavioral sensitization
Induction is prevented by either co-administering an NMDA
antagonist (glutamate stimulates NMDA receptors) or by
lesioning the PFC (the PFC sends glutamate projections to
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Dashed lines denote Glutamate projections 
Dotted lines denote GABA projections 
Solid lines denote DA projections
Figure 4. Schematic representation illustrating the 
widespread presence of glutamate (dashed lines) within the 
mesocortical and mesolimbic pathways. The location of DA 
Di-like receptors on glutamate pathways, as well as GABA 
(dotted lines) and DA (solid lines) projections are also 
shown. The PFC regulates the VTA indirectly via the PPTg, 
as direct PFC glutamatergic input to the VTA synapses on DA 
projections that form a feedback loop to the PFC. The 
reciprocal relationship between the VTA and The NAc can 
also be seen.
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both the VTA and the PPTg) (Cador et al., 1999; Karler,
Calder, Chaudhry, & Turkanis, 1989; Li et al., 1999;
Stewart & Druhan, 1993; Wolf et al., 1995). Glutamate
neurons are also fundamentally involved in the expression
of behavioral sensitization (Edley & Graybiel, 1983; Gnegy,
2000; Kozell & Meshul, 2001; Li et al., 1999; Montaron et
al., 1986; Pierce & Kalivas, 1997). Specifically,
glutamate increases DA release in the NAc by altering the
firing rate of DA neurons in the mesolimbic pathway
(Cornish & Kalivas, 2001a; Kalivas, 1995a; Kalivas &
Stewart, 1991; Kretschmer, 1999; Lokwan et al., 1999). The
altered firing rate results from: (a) glutamatergic
stimulation of NMDA receptors located on DA cell bodies in
the VTA (Gnegy, 2000; Kalivas, 1995a), (b) an NMDA-induced
subsensitivity of DA autoreceptors in the VTA (Grace, 1995;
Li et al., 1999; White & Wolf, 1991; Wolf, 1998), and (c)
an NMDA-induced hypersensitivity of Di-like receptors
located on GABA pathways that project bi-directionally
between the NAc and the ventral pallidum (VP) and uni-
directionally from the NAc to the VTA (see Fig. 4) (Bonci &
Williams, 1996; Gnegy, 2000; Kalivas, 1995b; Li et al.,
1999; Walaas & Fonnum, 1980; White et al., 1995; Wolf,
1998). The pervasive presence of glutamate throughout the
39
neural circuit underlying behavioral sensitization has lead
some authors to refer to glutamate as the "ubiquitous
regulator" (Li et al., 1999, p. 177; see also Danbolt,
2001; Karler et al., 1997; Laming, 1998; 'Wolf, 1998).
Behavioral.Sensitization, Learning, and 
W-methyl-D-aspartate Receptors
As discussed in Chapter Three, the strength of the
sensitized response is at least partially dependent on
Pavlovian associations formed between the drug and
environmental context (Kuczenski & Segal, 2001; Tirelli &
Terry, 1998). Specifically, it has been argued that
expression is context-dependent (Tirelli & Terry, 1998; but
see Vezina & Stewart, 1990), particularly when younger
animals or lower doses of psychostimulants are used
(Battisti et al., 2000; Zavala et al., 2000). Moreover,
even when context-independent sensitization occurs,
interoceptive feedback may serve as a discriminative
stimulus providing associative learning cues (Lienau &
Kuschinsky, 1997).
Learning is the result of enduring changes in neuronal
sensitivity due to the activation of both ionotropic (i.e.,
NMDA, AMPA, and kinate) and metabotropic (mGluR) glutamate
receptor subtypes in the hippocampus (Morris, Anderson,
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Lynch, & Baudry, 1986; Rickard & Ng, 1995; Riedel, 1996;
Vezina & Kim, 1999). A specific mGluR subtype, namely
mGluRi, has been implicated in hippocampus-based context-
dependent learning (Aiba et al., 1994). The hippocampus
provides glutamatergic input directly to the PFC, NAc, and
VTA (the same structures responsible for sensitization)
(Christie et al., 1987; Groenewegen, Becker, & Lohman,
1980; Mulder, Hodenpijl, & Lopes da Silva, 1998; Pierce &
Kalivas, 1997; Tzschentke & Schmidt, 2000). Evidence
supporting the idea that the hippocampus is important is
becoming more abundant. For example, blocking
glutamatergic input from the hippocampus prevents the
expression of behavioral sensitization (Aiba et al., 1994;
Kalivas, 1995a; but see Wolf, 1998). Moreover, a
relationship between hippocampal stimulation (which occurs
during learning) and glutamate content in the NAc has been
reported, with increased levels of glutamate found only in
rats given repeated drug exposures (Pierce et al., 1996).
Consistent with this finding, efforts to extinguish a
sensitized response are successful only when induction
involves a single psychostimulant exposure (Battisti et
al., 2000).
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Behavioral Sensitization and 
Neurotoxicity
DA is catabolized through oxidation (Mansour, Meador-
Woodruff, Lopez, & Watson, 1998), with high levels of DA
producing oxidative stress resulting in neurotoxicity
(Cohen, 1984; Yamamoto, Gudelsky, & Stephans, 1998).
Additionally, free radicals produced during oxidation
increase glutamate release that, in turn, produces more
free radicals (Pellegrini-Giampietro, 1994; Pellegrini-
Giampietro, Cherici, Alesiani, Carla, & Moroni, 1988, 1990;
Sonsalla, 1995; Yamamoto et al., 1998).
Excess extracellular glutamate has been implicated in
various neurological disorders and neurodegenerative
diseases (Choi, 1988; Lipton & Rosenberg, 1994). It has
been suggested that neuronal death caused by excess
glutamate (also known as excitotoxicity) (for a review see
Pellegrini-Giampietro, 1994) operates like a "domino
effect" (Choi, 1988; Lipton & Rosenberg, 1994).
Excitotoxicity has been characterized in this way because
the excessive amounts of-intracellular glutamate released
by a dying cell threaten the viability of all other cells
in close proximity. Therefore, the death of a cell via
excitotoxicity can perpetuate further neurotoxicity in an
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exponential fashion (Lipton & Rosenberg, 1994).
Additionally, elevated levels of extracellular glutamate
potentiate the neurotoxic effects of DA oxidation (Hoyt,
Reynolds, & Hastings, 1997; Yamamoto et al., 1998).
Because sustained increases in DA and glutamate occur in
behavioral sensitization (Pierce & Kalivas, 1997), and
because NMDA antagonists not only block induction (Calder
et al., 1989; Li et al., 1999; Stewart & Druhan, 1993;
Vezina & Queen, 2000), but protect against neuronal assault
%(Choi, 1988; Finnegan, Skratt, Irwin, & Langston, 1990;
Sonsalla, 1995; Sonsalla, Riordan, & Heikkila, 1991), it is
possible that sensitization may be a by-product of neuronal
damage (Peterson et al., 1997; Wolf, 1998; see also Itzhak,
Martin, & Ali, 2000; Wallace, Gudelsky, & Vorhees, 2001).
More specifically, glutamate excitotoxicity triggered by
repeated psychostimulant exposure may be a critical
mechanism underlying behavioral sensitization. Not only is
excitotoxity potentially important for understanding the
sensitization process, it also has implications for human
ATS abuse.
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CHAPTER SIX
SENSITIZATION, GLUTAMATE, AND
GLIAL CELLS
The Toxic Effects of 
Glutamate
It is possible that the expression of behavioral
sensitization is a manifestation of neuronal injury
(Peterson et al., 1997; Wolf, 1998; see also Itzhak et al.,
2000; Wallace et al., 2001). This is because sensitization
involves extracellular increases in both DA and glutamate
concentrations (Kalivas & Duffy, 1998; Kuczenski & Segal,
2001; Pierce & Kalivas, 1997). Increases in extracellular
DA cause oxidative stress that can lead to neurotoxicity,
particularly when followed by neuronal exposure to
glutamate (Cohen, 1984; Hoyt et al., 1997; Yamamoto et al.,
1998). Additionally, a positive feedback loop exists
between free radicals (produced through DA degradation) and
glutamate, whereby each increases the production of the
other (Pellegrini-Giampietro, 1994; Pellegrini-Giampietro
et al., 1990; Sonsalla, 1995).
The reciprocal action of the free-radical/glutamate 
feedback loop produces a sustained increase in glutamate
that depletes the adenosine triphosphate (ATP) required to
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transport and metabolize extracellular glutamate (Yamamoto
et al., 1998). This action further increases the
extracellular concentrations of glutamate due to lack of
uptake, reversal of transporters, or via leakage from
swollen cells (Danbolt, 2001; Kimelberg et al., 1990,
Kimelberg, Rutledge, Goderie, & Charniga, 1995; Lipton &
Rosenberg, 1994; Sykova, Hansson, Ronnback & Nicholson,
1998; Yamamoto et al., 1998). When high levels of
extracellular glutamate accumulate, the self-perpetuating
process of excitotoxicity begins, spreading at an
exponential rate as destroyed cells release their
intracellular stores of glutamate (Lipton & Rosenberg,
1994; Pellegrini-Giampietro, 1994).
The release of glutamate that occurs during
excitotoxicity bathes all proximal cells. This means that
both neurons and. glial cells (i.e., astrocytes and
oligodendrocytes) are vulnerable to the excitotoxic effects
of glutamate. There are several findings that support this
position. First, widespread neuronal damage occurs due to
the synergistic combination of DA and glutamate. Second,
glial cells, like neurons, uptake glutamate through
transporters (Danbolt, 2001; Pellegrini-Giampietro, 1994).
Third, glial cells, like neurons, contain glutamate and
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dopamine receptors (Cull-Candy & Wyllie, 1991; Pearce,
1991). And finally, glial cells have the ability to engage
in cross-communication with, as well as modulate the
activity of, neurons (Araque, Sanzgiri, Parpura, & Haydon,
1998; Carmignoto, 2000; Cull-Candy & Wyllie, 1991; Laming,
1998; Pearce, 1991).
Predictions
Despite a substantial body of evidence indicating that
glutamate toxicity affects both neurons and glia, few
studies have examined the effects of repeated
psychostimulant exposure on glial cell functioning.
Therefore, the current investigation examined changes in
glial and DA cell toxicity in amphetamine-sensitized rats.
Specifically, it was predicted that: (1) rats pretreated
with amphetamine would show a sensitized response after
acute amphetamine challenge; (2) rats pretreated with
amphetamine and challenged with saline, would show greater
locomotor activity (i.e., conditioned activity) than saline
controls; (3) rats pretreated with amphetamine would
exhibit increased gliosis (i.e., an increase in the number
of glial fibrillary protein [GFAP] immunoreactive cells),
indicating cellular neurotoxicity; (4) DA neurotoxicity
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would be evident in amphetamine-pretreated rats, with a
loss of DA transporters (-DAT) being used as a marker of DA
neurotoxicity (i.e., a decrease in the number of DAT
immunoreactive cells); and (5)- Glial cell toxicity would
also occur, as shown by a loss of glutamate transporter
subtype 1 (GLT-1) (i.e., a decrease in the number of GLT-1
immunoreactive cells).
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CHAPTER SEVEN
METHODS
Behavioral Methods
Subj ects
Subjects were 40 (n = 10 per group) adult male
Sprague-Dawley rats (Harlan, Indianapolis, IN). Rats
weighed between 225-249 g on arrival and were housed singly 
in a colony room maintained on a 12:12 light:dark cycle at
22°-24°C. Food and water were provided ad lib and rats
were treated in accordance with National Institute of
Health guidelines ("Principles of Laboratory Animal Care",
NIH Publication #85-23).
Drugs
d-Amphetamine was purchased from Sigma (St. Louis,
MO), dissolved in saline, and injected intraperitoneally
(i.p.) at a volume of 1 ml/kg.
Apparatus
Locomotor activity was monitored using commercially
available Coulbourn activity chambers (Coulbourn
Instruments, Allentown, PA). Chambers measured 25.5 x 25.5
x 41 cm and were constructed of Plexiglas. Chambers.
contained a removable plastic bottom and had an open top.
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Each chamber utilized an X-Y photobeam array with 16
photocells and detectors to determine the total distance
traveled (horizontal locomotor activity).
Procedure
Prior to any experimental manipulation, animals were
allowed to acclimate to the California State University
vivarium for a period of not less than 14 days. During
this time, the rats were handled daily. Rats were randomly
assigned to one of four treatment conditions:
saline/saline, amphetamine/saline, saline/amphetamine, or
amphetamine/amphetamine. Following assignment, the 7-day
pretreatment phase began. During pretreatment, rats
received a single daily injection of saline or amphetamine
(2.0 mg/kg, i.p.) at approximately the same time each day.
Immediately following injections, rats were individually
placed in activity chambers for a period of 60 min, with
distance traveled measured in 5 min increments.
A single test day occurred after a 10-day abstinence
period. On test day, rats were given a challenge injection
of either saline or amphetamine (0.5 mg'/kg, i.p.).
Immediately following injections, rats were individually
placed in activity chambers for'120 min, with distance
traveled measured in 5 min increments.
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Statistics
Distance traveled data from the drug pretreatment
phase was analyzed using a 2 x 7 (Pretreatment x Day)
repeated measures analysis of variance (ANOVA). Test day
data was analyzed using a 2 x 2 x 24•(Pretreatment x Test
Treatment x Time [5 min blocks]) repeated measures ANOVA.
Post hoc analysis of data from the drug pretreatment phase
and test day was made using Tukey tests (p < .05).
Immunohistochemistry Methods
Antibodies and Supplies
Primary antibodies for three different proteins (glial
fibrillary acidic protein [GFAP], dopamine transporter
[DAT], and glutamate transporter [GLT-1]) were used. Anti-
glial fibrillary acidic protein, anti-dopamine transporter
antibody, and anti-glial transporter antibody was purchased
from Chemicon (Temecula, CA). Secondary antibodies
consisted of either biotinylated rabbit (for GFAP and DAT)
or biotinylated guinea pig (for GLT-1) antiserum (Vector
Laboratories, Burlingame, CA). An avidin-biotin-
horseradish peroxidase conjugate kit (ABC Vectastain
Kit; Vector Laboratories, Burlingame, CA) was also
required.
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Procedure
Rats were anesthetized with phenobarbital and rapidly
perfused with 4% paraformaldehyde after completion of
behavioral assessment on the test day. Following a
postfixation period, 75 p.1 coronal sections were taken from
each brain using a cryostat (Mikron, Nussloch, Germany)
maintained at -25°C (± 1°C).
To control for variability between assays, all assay
procedures were done in sets of four, so that each
treatment condition was represented. Sections were
incubated in peroxidase solution (3% hydrogen peroxide and
10% methanol), followed by three washes in 0.1 M phosphate
buffer (PB). All washes lasted 5 min. Sections were then
incubated in goat serum solution (GSS; 1% goat serum and
0.1% Triton X-100 in PB) for 1 hr, followed by one wash in
PB. Control sections were placed in GSS void of any
primary antibody. All other sections were incubated for
48-72 hr with one of three primary antibodies (i.e., GFAP
[1:2000 in GSS]; DAT [1:3750 in GSS]; GLT-1 [1:5000 in
GSS]). After completion of the primary antibody
incubation, sections were washed in PB three more times.
Sections were then transferred into either rabbit (GFAP and
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DAT [1:200 in GSS]) or guinea pig (GLT-1 [1:5000 in GSS])
antiserum and allowed to incubate 1 hr. Sections then
received three more washes in PB followed by 1 hr
incubation in ABC solution (1:200 in GSS). After this
final incubation, sections were washed three times in PB.
Sections were then stained using a DAB/hydrogen peroxide
solution followed by three final washes in PB. Sections
were then mounted on Superfrost Plus slides (Fisher,
Philadelphia, PA), air-dried, dehydrated, and coverslipped
with Depex.
Sections were then examined for GFAP, DAT, and GLT-1
immunoreactivity. Quantification was conducted manually at
a magnification of x40 by researchers blind to treatment
condition. The brain regions assessed included cingulate
cortex, CAi and CA3 regions of the hippocampus, NAc core and
shell, and the ventral and dorsal caudate-putamen.
Statistics
GFAP, DAT, and GLT-1 immunoreactivity was analyzed
using separate 2x2 (Pretreatment x Test Treatment) ANOVAs
for each brain region. Post hoc analysis of the
immunohistochemistry data was made using Tukey tests (p <
. 05) .
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CHAPTER EIGHT
RESULTS AND DISCUSSION
Behavioral Results
Pretreatment Phase
During the pretreatment phase, rats given 2.0 mg/kg
amphetamine displayed more horizontal locomotor activity
than did saline controls (see Figure 5) (Pretreatment Drug
main effect, F1/38=232.95, p < 0.01). In addition,
amphetamine-pretreated rats showed a general increase in
distance traveled over the pretreatment phase, while saline
controls showed a general decline (Pretreatment Drug x Day
interaction, F6, 228=12.24, p < 0.01).
Test Day
Overall, rats given 2 mg/kg amphetamine during the
pretreatment phase showed more test day locomotor activity
than rats pretreated with saline (see Figure 6)
(Pretreatment Drug main effect, Flr 3g=25.53, p < 0.01;
Pretreatment Drug x Time interaction, F23, 828=1 - 69, p <
0.05). In addition, rats receiving a challenge injection
of 0.5 mg/kg amphetamine on the test day exhibited more
horizontal locomotor activity than rats receiving a
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Pretreatment Phase
Figure 5. Mean (± SEM) distance traveled (cm) of rats (n 
20 per group) receiving either a daily i.p. injection of 
saline or 2.0 mg/kg amphetamine over seven pretreatment 
days. Measurement was taken during the 60 min period 
immediately following injection.
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2,000
Test Day
Figure 6. Mean (± SEM) distance traveled (cm) of saline- 
or amphetamine-pretreated rats (n = 10 per group) on test 
day (these are the same rats as described in Figure 1). 
Measurement was conducted for 120 min immediately following 
a challenge injection of either saline or 0.5 mg/kg 
amphetamine.
I
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challenge injection of saline (Challenge Drug main effect,
Fi,36=26.61, p < 0.01; Challenge Drug x Time interaction, F23,
828=5.59, p < 0.01). Separate ANOVAs indicated that
amphetamine pretreatment resulted in a sensitized locomotor
response on the test day. More specifically, amphetamine-
pretreated rats given a challenge injection of amphetamine
(filled triangles) exhibited more test day locomotor
activity than rats given amphetamine for the first time on
the test day (filled circles) (Pretreatment Drug main
effect, Fi, 18=17.75, p < 0.01). Conditioned activity was
also apparent, as rats pretreated with amphetamine and
challenged with saline (open triangles) were more active
than saline controls (open circles) (Pretreatment Drug main
effect, Fi, 18=8.25, p < 0.05).
Discussion of 
Behavioral Results
In terms of the behavioral data, two original
predictions were made regarding behavioral sensitization
and conditioned activity. Specifically, it was
hypothesized that rats pretreated with amphetamine would
show a sensitized locomotor response after acute
amphetamine challenge. This hypothesis was supported. The
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AMPH/AMPH group demonstrated greater horizontal locomotion
than did the SAL/AMPH group. This indicates a sensitized
response to the sympathomimetic properties of amphetamine.
It was also predicted that rats pretreated with amphetamine
and challenged with saline would demonstrate conditioned
activity. This prediction was also supported as the
AMPH/SAL group exhibited greater locomotion than did the
SAL/SAL group. This finding indicates the presence of a
conditioning component operating upon the sensitized
animals.
Immunohistochemistry Results
Glial Fibrillary Acidic Protein Assay
Rats pretreated with 2 mg/kg amphetamine sustained
neurotoxicity in the ventral and dorsal caudate-putamen
(CP) (see Figure 7) as well as the CA3 region of the
hippocampus (see Figure 8). In the ventral CP,
pretreatment with amphetamine resulted in an increase in
GFAP irrespective of challenge injection (Pretreatment Drug
main effect, Fi,27=10.20, p < 0.01). Similarly, pretreatment
with amphetamine enhanced gliosis (i.e., the number of
GFAP-immunoreactive cells) in both the dorsal CP and CA3 of
saline-challenged rats (Pretreatment Drug x Test Drug
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Figure 7. .Mean number (± SEM) of anti-glial fibrillary 
acidic protein (GFAP) immunoreactive cells found in the 
dorsal caudate-putamen, ventral caudate-putamen, nucleus 
accumbens core, and nucleus accumbens shell for both 
saline- and amphetamine-pretreated rats (n = 10 per group). 
Open bars represent saline challenge; hatched bars indicate 
amphetamine challenge. aSignificantly different from 
saline-challenged rats (p < 0.05). bSignificantly different 
from saline-saline group (p <,0.05). cSignificantly 
different from saline- pretreated rats (p < 0.05).
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Figure 8. Mean number (± SEM) of anti-glial fibrillary 
acidic protein (GFAP) immunoreactive cells found in 
hippocampal CAi, hippocampal CA3, dentate gyrus, and 
cingulate cortex for both saline- and amphetamine- 
pretreated rats (n = 10 per group). Open bars represent 
saline challenge; hatched bars indicate amphetamine 
challenge. aSignificantly different from saline-challenged 
rats (p < 0.05). bSignificantly different from saline- 
saline group (p < 0.05).
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interaction, Fi,27=7.72, p = 0.01; Fi( 27=4.46, p < 0.05,
respectively).
In addition, a challenge injection of 0.5 mg/kg
amphetamine resulted in higher levels of GFAP in the dorsal
CP, as well as the NAc core and cingulate cortex (Test Drug
main effect, Fi,27=4.57, p < 0.05; Fi,27=8.66, p < 0.01;
Fi,27=18.55, p < 0.001, respectively).
Dopamine Transporter Assay
Examination of the CAi region of the hippocampus
revealed increased numbers of DAT-immunoreactive cells in
those rats repeatedly exposed to amphetamine during the
pretreatment phase (Pretreatment Drug main effect,
Hi, 27=4.42, p < 0.05; see Figure 9). Acute effects were also
evident, as an increase in DAT was found in the amygdala,
dentate gyrus, dorsal CP, and cingulate cortex of those
rats given a challenge injection of amphetamine on test day
(Test Drug main effect, Fi,27=4,. 57, p < 0.05; Fi,27=8.76, p <
0.01, respectively; see Figures 9 and 10).
Glutamate Transporter Assay
Neither amphetamine pretreatment nor challenge caused
a significant decrease in the number of GLT-1
immunoreactive cells in any of the brain areas examined
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Pretreatment Condition
Figure 9. Mean number (±-SEM) of dopamine transporter 
(DAT) immunoreactive cells found in hippocampal CAi, 
hippocampal CA3, dentate gyrus, and basolateral amygdala for 
both saline- and amphetamine-pretreated rats (n = 10 per 
group). Open bars represent saline challenge; hatched bars 
indicate amphetamine challenge. aSignificantly different 
from saline-challenged rats (p < 0.05). bSignificantly 
different from saline-saline group (p < 0.05). 
cSignificantly different from saline- pretreated rats (p < 
0.05).
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Figure 10. Mean number ■ (± SEM) of dopamine transporter 
(DAT) immunoreactive cells found in the dorsal caudate- 
putamen, ventral caudate-putamen, nucleus accumbens core, 
and cingulate cortex, for both saline- and amphetamine- 
pretreated rats (n = 10 per group). Open bars represent 
saline challenge; hatched bars indicate amphetamine 
challenge. aSignificantly different from saline-challenged 
rats (p < 0.05).
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Figure 11. Mean number (+ SEM) of glutamate transporter 
(GLT-1) immunoreactive cells found in the hippocampal CAi, 
hippocampal CA3, nucleus accumbens core, cingulate cortex, 
dorsal and ventral caudate-putamen for both saline- and 
amphetamine-pretreated rats (n = 10 per group).
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(ventral and dorsal CP, NAc, hippocampus, cingulate cortex
and prefrontal cortex; see Figure 11).
Discussion of
Immunohistochemistry Results
Three original hypotheses were made regarding changes
in neuronal and glial functioning. First, it was predicted
that rats pretreated with amphetamine would exhibit
increased gliosis. This prediction was supported because a
significant increase in GFAP was observed in both and
ventral and dorsal CP of amphetamine-pretreated rats. This
increase in GFAP suggests that amphetamine does induce
gliosis in specific regions of the rat brain.
Second, it was hypothesized that amphetamine-
pretreated rats would exhibit DA toxicity as indicated by a
decrease in DAT. This hypothesis was not supported as DAT
immunoreactive cells within the CAi region of the
hippocampus increased rather than decreased following
amphetamine pretreatment. Additionally, increases in DAT
were also observed in the amygdala, dentate gyrus, dorsal
CP and cingulate cortex following amphetamine challenge.
This increase in DAT immunoreactive cells suggests that DAT
transporters may exhibit compensatory changes after
amphetamine treatment.
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Lastly, it was predicted that amphetamine-pretreated
rats would exhibit glial toxicity as indicated by a
decrease in GLT-1. This prediction was not supported,
amphetamine pretreatment. The reason for this lack of
effect is uncertain.
as
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CHAPTER NINE
GENERAL DISCUSSION
Rationale
Behavioral sensitization is known to involve increases
in both DA and glutamate in various brain regions (see
Chapter 4). The current investigation was undertaken to
determine whether the toxic interaction of these two
neurotransmitters underlies behavioral sensitization. The
importance of toxicity for behavioral sensitization has
garnered support, as a feedback loop exists between DA and
glutamate. Specifically, the stimulation of DA receptors
increase glutamate release, and glutamate enhances DA
release (Kalivas & Duffy, 1998; Mereu et al., 1991;
Takahata & Moghaddam, 2000; for a fuller discussion see
Chapter 4). The break down of DA produces cell-damaging
ROS and stimulates glutamate release, while excess
glutamate depletes cellular ATP (Pellegrini-Giampietro,
1994; Pellegrini-Giampietro et al., 1988, 1990; Wolf, Xue,
Li, & Wavak, 2000; Yamamoto et al., 1998). ATP depletion,
in turn, further increases extracellular glutamate
(Anderson & Swanson, 2000; Lipton & Rosenberg, 1994).
Thus, the escalation of DA and glutamate is synergistic,
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because cells stressed by the DA oxidation process are more
vulnerable to glutamate toxicity (Hoyt et al., 1997;
Yamamoto et al., 1988). In sum, repeated exposure to
amphetamine causes both neurotoxicity (through the
synergistic effects of'DA and glutamate) and behavioral
sensitization. Determining whether this relationship is
more than correlative was the purpose of this thesis.
In the present study, toxicity was measured using
three immunohistochemistry assays. To provide an indice of
general neurotoxicity, glial fibrillary protein (GFAP) was
assessed. Due to the existence of a feedback loop between
DA and glutamate, and previous findings that excitotoxicity
can occur following increases in extracellular glutamate
concentrations, it was expected that GFAP levels would
increase following amphetamine exposure. Assessment of
amphetamine-induced DA neurotoxicity was accomplished by
measuring DA transporters (DAT). Neurotoxic doses of
psychostimulants have been shown to decrease DAT levels
(indicating DA neuron loss). Thus, it was predicted that
an amphetamine regimen sufficient to induce behavioral
sensitization would decrease DAT levels. Because excess DA
and glutamate impact all proximal cells including glia,
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glial glutamate transporter levels were examined as a
measure of glial cell loss.
Evidence for Amphetamine-Induced 
Behavioral Sensitization
Behavioral sensitization was induced in amphetamine-
pretreated rats, and both pharmacological and learning
components were evident. Specifically, rats repeatedly
exposed to amphetamine exhibited an increase in horizontal
locomotion over pretreatment days. On test day, an
enhanced response to the pharmacological effects of the
drug were observed, because sensitized rats given an
amphetamine challenge (the AMPH-AMPH group) displayed a
significantly greater level of locomotor activity than did
those rats experiencing acute amphetamine exposure (the
SAL-AMPH group). Learning components (i.e., conditioned
activity) were also evident, in that sensitized rats
receiving a challenge injection of saline on test day (the 
AMPH-SAL group) exhibited significantly greater locomotor
activity than did control rats that had never been exposed
to the drug (the SAL-SAL group).
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Assays: Findings and Interpretations
Acute and Repeated Amphetamine Exposure Results in
Gliosis
Amphetamine-exposed rats were expected to show 
gliosis. Acute exposure to amphetamine caused increased
GFAP in three brain areas: the cingulate cortex, dorsal CP,
and NAc core. More interesting, however, was the finding
that amphetamine pretreatment caused gliosis in the CA3 area
of the hippocampus as well as both the ventral and dorsal
CP. In the CA3 region of the hippocampus, gliosis occurred
after amphetamine challenge, but only in those rats
chronically exposed to amphetamine during the pretreatment
phase. Similarly, amphetamine pretreatment caused increased
GFAP in the ventral and dorsal CP of both amphetamine- and
saline-challenged rats.
Overall, GFAP findings were consistent with original
expectations, and the increased number of GFAP
immunoreactive cells suggests two possible interpretations.
First, the anatomical pattern of gliosis along the basal
ganglia-thalamocortical "motor" pathway is consistent with
published assertions that neuronal injury is the basis for
the expression of behavioral sensitization (Peterson et
al., 1997; Wolf, 1998). The basal ganglia-thalamocortical
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"motor" pathway extends from the cingulate cortex to the
core of the NAc and the adjoining CP and projects to
various motor cortices (Alexander & Crutcher, 1990; Zahm &
Brog, 1992). The core of the NAc is particularly
susceptible to.neurotoxins.and is thought to be the locus
of stimulant-induced locomotion, as well as the area
responsible for determining the saliency of response reward
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in associative learning (Boye, Grant, & Clarke, 2001;
Broening, Pu, & Vorhees, 1997; Corbit, Muir, & Balleine,
2001). Second, it has been proposed that gliosis may
indicate the activation of neuroprotective mechanisms as
astroctytes contain antioxidants and have the ability to
both synthesize and release neurotrophins (Deng, Ladenheim,
Tsao, & Cadet, 1999). Therefore, GFAP concentrations may
not simply reflect the degree of neurotoxicity, instead
GFAP may serve as a neuroprotective mechanism depending on
the level of environmental toxicity. In terms of the
present study, it is possible that the amphetamine-induced
increases in GFAP are more indicative of a neuroprotective
response than actual cell loss.
7 0
Glutamate Transporter and Dopamine Transporter
Assays Yield Counterintuitive Findings
The GLT-1 and DAT findings were not consistent with
initial predictions that repeated amphetamine exposure
would induce behavioral sensitization via injury to DA
neurons and glial cells. Specifically, amphetamine
treatment did not cause significant changes in the number
of GLT-1 immunoreactive cells, while there was an increase,
rather than a decrease, in the number of DAT immunoreactive
cells. Although the reasons for the null GLT-1 findings
are unknown, it is possible that the GLT-1 marker may not
be sufficiently sensitive to detect excitotoxic-induced
changes in glial glutamate transporters within the present
paradigm. In particular, there are disagreements regarding
the cellular and regional specificity of the various
glutamate transporter subtypes (e.g., GLT-1, GLAST, EAAC1),
as well as contradictory results regarding their expression
(Chen et al., 2002; Nakajima et al., 2001; Perego et al.,
2000; Redecker & Pabst, 2000'; Rothstein et al. , 1994).
In contrast to the null GLT-1 findings, amphetamine
treatment caused an increase in DAT within the CAX region of
the hippocampus, the basolateral amygdala, the dentate
gyrus, the dorsal portion of the CP, and the cingulate
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cortex. DAT levels in-CAi were enhanced only when rats
received both amphetamine pretreatment and amphetamine
challenge. Within the dentate gyrus, DAT increases were
limited to the saline-pretreated rats administered a test-
day amphetamine challenge; while amphetamine challenged
rats (i.e., the SAL-AMPH and the AMPH-AMPH groups) showed
increased DAT in the amygdala, the dorsal portion of the
CP, and the cingulate cortex.
Dopamine Transporters and Augmented Dopamine
Release in Sensitized Rats
The increased DAT levels are surprising considering
the large body of literature demonstrating DA neurotoxicity
following amphetamine, methamphetamine, or ROS exposure
(Fleckenstein et al., 1999; Fleckenstein, Metzger, Beyeler,
Gibb, & Hanson, 1997; Gulley, Doolen & Zahniser, 2002;
Nakayama, Koyama, & Yamashita, 1993; Ricaurte, Guillery,
Seiden, Schuster, & Moore, 1982; Wagner et al., 1980).
However, some researchers have shown that DAT levels within
the VTA and the SN increase following amphetamine
withdrawal of 7 to 14 days (Lu & Wolf, 1997; Shilling,
Kelsoe, & Segal, 1997) . Thus, it is possible that an
amphetamine-induced increase in DA transporters is an
adaptive modification to offset neural loss, as the DAT
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assay does riot directly measure the number of dopamine
neurons (Deng et al., 1999). Alternatively, this apparent-
modification in DA transporter numbers may be a transitory
means of counteracting the inactivation of pre-existing
transporters that occurs during the metabolization of DA
and subsequent ROS formation (Berman, Zigmond, & Hastings,
1996; Fleckenstein, Metzger, Beyeler,.Gibb, & Hanson,-
1997). A related possibility is that DA transporters may
migrate from inside the cell to the cell surface as an
initial response to increases in synaptic DA levels (Daws
et al., 2002; Melikian & Buckley, 1999). According to this
explanation, amphetamine-induced increases in DAT levels
are not a result of toxicity, but are a compensatory
response to the increased amount of syriaptic 'DA.
Regardless of the mechanism driving the DA transporter
increases, up-regulation may have important implications.
Specifically, an up-regulation of DA transporters within
the CP (see Figures 9 and 10) is potentially significant,
as elevated DA in this structure may be necessary for
behavioral sensitization (Berke & Hyman, 2000; Lu & Wolf,
1997). In other words, a psychostimulant-induced increase
in DA transporters may be the mechanism by which augmented
levels of synaptic DA is released in sensitized rats during
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amphetamine 'challenge (Lu & Wolf, 1997) . This explanation 
seems plausible, as reverse transport is the primary
mechanism of amphetamine-induced DA release (Jones, 1998).
Increased DAT in the amygdala, hippocampal formation,
CP, and cingulate -cortex may be involved in both the
learning and motivational aspects of behavioral
I
sensitization. This is because: (1) DA neurons have been
implicated in both long-term potentiation and depression
(Alexander, 1994); (2) Amphetamine enhances both spatial
and cued memory retention when injected into the
hippocampus and caudate, respectively (Packard, Cahill, &
McGaugh, 1994); (3) Mice with reduced DA and DAT levels
also show a'diminished capacity to develop psychostimulant-
induced conditioned place preferences (Itzhak & Ali, 2002);
and (4) The brain areas showing increased DAT levels
constitute portions of the basal ganglia-thalamocortical
"limbic" circuit (Alexander, Crutcher, & DeLong, 1990).
Importantly, the basal ganglia-thalamocortical circuit not
only underlies emotional and motivational processes, but
has been linked to both drug craving and drug-seeking
behaviors (Alexander et al., 1990; Berke & Hyman, 2000; Di
Chiara & Imperato, 1988). Therefore, it appears that brain
areas with elevated DAT levels serve dual roles, thus
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providing compelling.evidence for an overlap between 
learning, memory, and motivational processes in both
behavioral sensitization and addiction. This idea of a
functional duality is consistent with recent findings of
increased neural activity in ' the'basolateral amygdala, the
CAi region of the hippocampus, and the dentate gyrus of rats
following drug-seeking behavior in a familiar drug-paired
environment (Neisewander et al., 20.00). Furthermore, when
given a psychostimulant-challenge prior to exposure to a
drug-paired environment, increases in neuronal activity
were found within the dorsal CP (Neisewander et al., 2000).
It seems more than coincidental that these are the very
same brain areas that showed elevated DAT levels after
amphetamine exposure (see Figures 7 and 8).
Cellular Changes and Addiction
While increases in DAT have been found in the early
periods following amphetamine exposure (Lu & Wolf, 1997;
Shilling, Kelsoe, & Segal, 1997), a common finding is that
an escalating or high-dose drug regimen causes significanti
reductions in DA transporter sites (Fleckenstein et al.,
1999; Nakayama et al., 1993; Ricaurte et al., 1982; Wagner
et al., 1980). This suggests that DA transporters may up-
I
regulate in;an effort to preserve homeostasis, with
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sustained excesses of DA eventually overwhelming the system
1
resulting in cell death (see Koff, Shuster, & Miller,
1994). It is possible'that the degree of cell loss is
important for both stereotypic behavior and tolerance.
This is because intensity of stereotypic behavior is
positively correlated with drug.dosage levels (Kuczenski & 
Segal, 1988; Segal & Kuczenski, 1987; Segal et al., 1995).
Likewise, tolerance, as opposed to sensitization, occurs
when psychostimulant administration is continuous rather
than intermittent (Blanchet et al., 1995; Kalivas & Duffy,
1993; Nelson-& Ellison, 1978; Stewart & Badiani, 1993;
Strakowski et al., 1996)
Stereotypic behaviors and tolerance are also observed
in humans; and, these phenomena appear related to cell
loss. More ■ specifically, human addicts spend inordinate
amounts of time ensuring drug attainment and often engage
in ritualistic drug-taking behaviors, both of which are
stereotypic in nature (Ellinwood, King, & Lee, 1998).
Likewise, those addicted to psychostimulants report a
reduction in the euphoric effects of drug exposure over
I
time, clearly indicating tolerance (Topp & Darke, 1997).
Drug tolerance results in an ever-higher escalation in drug
dosage levels presumably exerting greater cellular stress.
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That stereotypy and tolerance correspond with cell loss in
i
humans is supported by findings of substantial reductions
in DAT levels within the brains of chronic methamphetamine
users (Sekine et al., 2001; Volkow et al., 2001; Wilson et
al., 1996).■
Summary
In conclusion, previous research has demonstrated a
synergistic relationship between dopamine and glutamate
that might serve as the basis for amphetamine-induced cell
loss. The purpose of this thesis was to assess whether
amphetamine-induced neurotoxicity may provide a
foundational basis for behavioral sensitization.
Therefore, I examined the effects of both acute and
repeated amphetamine exposure on GFAP, GLT-1, and DAT
levels. Consistent with initial predictions, GFAP, a
measure of general neurotoxicity, was elevated after
repeated amphetamine treatment. However, GLT-1, an
indirect measure of glial cell viability, was unaffected by
amphetamine exposure. And, DAT levels, a commonly used
indirect measure of DA neurotoxicity, was elevated, rather
than diminished, following amphetamine treatment.
Therefore, although neurotoxicity is perhaps partially
77
responsible for behavioral sensitization, it appears that
intermediate neuroprotective and/or homeostatic processes
(e.g., increases in transporter numbers) may produce the
range of behaviors that exist within the
sensitization/tolerance continuum.
I
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